Mounjaro and Zepbound contributed more than $10 billion to the $11.98 billion in sales Lilly recorded for key products in the third quarter, despite price decreases for the GLP-1 medicines.
Zepbound Topples Sales King Keytruda as Lilly Reports 54% YoY Revenue Rise for Q3